Holen Sie sich die Stockscreener-App
1.23
7.89%
0.09
Schlusskurs vom Vortag:
$1.14
Offen:
$1.16
24-Stunden-Volumen:
90,656
Relative Volume:
0.50
Marktkapitalisierung:
$69.62M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-131.52M
KGV:
-0.691
EPS:
-1.78
Netto-Cashflow:
$-107.56M
1W Leistung:
+1.65%
1M Leistung:
+46.20%
6M Leistung:
+62.91%
1J Leistung:
-74.43%
1-Tages-Spanne:
$1.1357
$1.23
1-Wochen-Bereich:
$1.1042
$1.255
52-Wochen-Spanne:
$0.6101
$5.53
Prelude Therapeutics Inc Stock (PRLD) Company Profile
Firmenname
Prelude Therapeutics Inc
Sektor
Branche
Telefon
(302) 467-1280
Adresse
175 INNOVATION BOULEVARD, WILMINGTON
Vergleichen Sie PRLD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
1.23 | 64.52M | 0 | -131.52M | -107.56M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-19 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-06-20 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2024-03-13 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-02-20 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-12-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2022-11-21 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-09-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-07-29 | Eingeleitet | Jefferies | Buy |
| 2022-03-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-02-28 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-10-08 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-07-27 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-04-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-09 | Eingeleitet | Barclays | Overweight |
| 2020-11-20 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-10-20 | Eingeleitet | BofA Securities | Buy |
| 2020-10-20 | Eingeleitet | Goldman | Neutral |
| 2020-10-20 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Prelude Therapeutics Inc Aktie (PRLD) Neueste Nachrichten
Published on: 2025-09-06 20:49:10 - Newser
What’s next for Prelude Therapeutics Incorporated stock priceMarket Risk Report & AI Enhanced Execution Alerts - Newser
Published on: 2025-09-06 13:48:12 - Newser
Is Prelude Therapeutics Incorporated showing signs of accumulation2025 Analyst Calls & Weekly High Return Forecasts - Newser
Can Prelude Therapeutics Incorporated stock double in the next yearQuarterly Earnings Summary & Consistent Income Trade Recommendations - خودرو بانک
Is Prelude Therapeutics Incorporated still worth holding after the dipQuarterly Profit Summary & High Accuracy Swing Trade Signals - Newser
What are Prelude Therapeutics Incorporated’s recent SEC filings showingTrade Exit Summary & Safe Capital Preservation Plans - خودرو بانک
Will Prelude Therapeutics Incorporated continue its uptrend2025 Trading Volume Trends & Real-Time Volume Surge Alerts - Newser
What’s the RSI of Prelude Therapeutics Incorporated stock2025 Short Interest & Weekly High Momentum Picks - خودرو بانک
Is Prelude Therapeutics Incorporated stock forming a cup and handle2025 Volume Leaders & Safe Capital Growth Stock Tips - خودرو بانک
Can Prelude Therapeutics Incorporated continue delivering strong returnsJuly 2025 Big Picture & Advanced Technical Analysis Signals - خودرو بانک
Prelude Therapeutics Incorporated stock trend forecastEarnings Overview Summary & Accurate Intraday Trading Signals - Newser
Is now a turning point for Prelude Therapeutics IncorporatedQuarterly Performance Summary & Weekly Breakout Stock Alerts - Newser
How to interpret RSI for Prelude Therapeutics Incorporated stock2025 Buyback Activity & Daily Profit Focused Screening - Newser
Will Prelude Therapeutics Incorporated outperform the marketMarket Rally & Verified Chart Pattern Signals - Newser
How to manage a losing position in Prelude Therapeutics IncorporatedWeekly Profit Summary & Verified Entry Point Detection - Newser
What to expect from Prelude Therapeutics Incorporated in the next 30 daysJuly 2025 Earnings & High Win Rate Trade Alerts - Newser
Prelude Therapeutics Incorporated’s volatility index tracking explainedChart Signals & Consistent Profit Alerts - Newser
Real time scanner hits for Prelude Therapeutics Incorporated explainedJuly 2025 Recap & Technical Buy Zone Confirmations - Newser
What MACD signals say about Prelude Therapeutics Incorporated2025 Volatility Report & Weekly High Return Opportunities - Newser
Can Prelude Therapeutics Incorporated reach resistance levels soon2025 Buyback Activity & Fast Momentum Entry Tips - خودرو بانک
Market Rankings: What drives Prelude Therapeutics Incorporated’s stock priceInsider Selling & Weekly Watchlist of Top Performers - خودرو بانک
How sentiment analysis helps forecast Prelude Therapeutics IncorporatedWatch List & Consistent Growth Equity Picks - Newser
Evaluating Prelude Therapeutics Incorporated with trendline analysisJuly 2025 Big Picture & Risk Controlled Daily Plans - Newser
Visual trend scoring systems applied to Prelude Therapeutics Incorporated2025 Historical Comparison & Precise Swing Trade Entry Alerts - Newser
Detecting price anomalies in Prelude Therapeutics Incorporated with AIJobs Report & Free Community Consensus Stock Picks - Newser
Quantitative breakdown of Prelude Therapeutics Incorporated recent moveQuarterly Earnings Report & Risk Managed Investment Strategies - Newser
Is Prelude Therapeutics Incorporated backed by strong institutional buyingJuly 2025 Movers & Daily Volume Surge Trade Alerts - خودرو بانک
Real time social sentiment graph for Prelude Therapeutics IncorporatedEarnings Performance Report & Free Low Drawdown Momentum Trade Ideas - Newser
Prelude Therapeutics Incorporated stock outlook for YEAR2025 Macro Impact & Daily Stock Momentum Reports - Newser
Does Prelude Therapeutics Incorporated fit your quant trading modelEarnings Recap Report & Daily Growth Stock Tips - Newser
Does Prelude Therapeutics Incorporated meet Warren Buffett’s criteriaWeekly Investment Summary & Daily Stock Momentum Reports - خودرو بانک
Investment Review: What drives Prelude Therapeutics Incorporated’s stock priceWeekly Risk Report & Smart Swing Trading Alerts - خودرو بانک
Prelude Therapeutics Incorporated stock volume spike explained2025 Fundamental Recap & AI Driven Stock Price Forecasts - Newser
Can Prelude Therapeutics Incorporated keep up with sector leadersWeekly Trading Summary & Daily Volume Surge Signals - خودرو بانک
Finanzdaten der Prelude Therapeutics Inc-Aktie (PRLD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Prelude Therapeutics Inc-Aktie (PRLD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Vaddi Krishna | CEO |
Mar 25 '25 |
Buy |
0.69 |
675,000 |
467,438 |
1,999,296 |
| Vaddi Krishna | CEO |
Mar 21 '25 |
Buy |
0.73 |
15,000 |
10,959 |
1,324,296 |
| Vaddi Krishna | CEO |
Mar 20 '25 |
Buy |
0.73 |
5,416 |
3,950 |
1,309,296 |
| Vaddi Krishna | CEO |
Mar 14 '25 |
Buy |
0.75 |
29,999 |
22,631 |
1,294,774 |
| Vaddi Krishna | CEO |
Mar 17 '25 |
Buy |
0.75 |
9,106 |
6,829 |
1,303,880 |
| Vaddi Krishna | CEO |
Mar 13 '25 |
Buy |
0.72 |
50,000 |
35,820 |
1,264,775 |
| Vaddi Krishna | CEO |
Mar 12 '25 |
Buy |
0.71 |
47,500 |
33,744 |
1,214,775 |
| Vaddi Krishna | CEO |
Dec 31 '24 |
Buy |
1.21 |
5,000 |
6,044 |
142,553 |
| Vaddi Krishna | CEO |
Dec 30 '24 |
Buy |
1.20 |
10,000 |
12,000 |
137,553 |
| Combs Andrew | Chief Chemistry Officer |
Dec 23 '24 |
Buy |
1.37 |
60,000 |
82,002 |
377,623 |
1.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):